{"id":48542,"date":"2025-11-18T15:03:24","date_gmt":"2025-11-18T07:03:24","guid":{"rendered":"https:\/\/flcube.com\/?p=48542"},"modified":"2025-11-18T15:03:25","modified_gmt":"2025-11-18T07:03:25","slug":"resight-therapeutics-secures-tens%e2%80%91millions-rmb-angel-round-to-accelerate-ipsc%e2%80%91derived-corneal-endothelial-cell-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48542","title":{"rendered":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy"},"content":{"rendered":"\n<p><strong>Resight Therapeutics<\/strong>, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an <strong>Angel\u2011stage financing round<\/strong> led by <strong>Hofon Capital<\/strong> with co\u2011investment from the <strong>Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund)<\/strong>. The round raised <strong>tens of millions of RMB<\/strong> and will fund the company\u2019s lead <strong>iPSC\u2011derived corneal endothelial cell (CEC) therapy<\/strong> as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Round Type<\/strong><\/td><td>Angel round<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Hofon Capital<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>Hangzhou Science &amp; Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund)<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>\u2248\u202f\u00a530\u202fmillion (\u2248\u202fUS$4.2\u202fmillion) \u2013 \u201ctens of millions of RMB\u201d<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>\u2022 Advance lead iPSC\u2011derived CEC therapy pipeline<br>\u2022 Expand early\u2011stage pipeline (retinal, corneal, other ocular indications)<br>\u2022 Scale AI\u202f+\u202fCompound Reprogramming platform<\/td><\/tr><tr><td><strong>Closing Date<\/strong><\/td><td>15\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-amp-technology-snapshot\">Company &amp; Technology Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> September\u202f2024<\/li>\n\n\n\n<li><strong>Focus:<\/strong> Cell\u2011therapy drugs for high\u2011unmet\u2011need ophthalmic diseases (cornea, retina).<\/li>\n\n\n\n<li><strong>Core Platforms:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>iPSC Differentiation Platform<\/strong> \u2013 proprietary protocols to generate functional corneal endothelial cells from induced pluripotent stem cells.<\/li>\n\n\n\n<li><strong>AI\u2011Powered Compound Reprogramming<\/strong> \u2013 machine\u2011learning models accelerate discovery of small\u2011molecule enhancers that improve cell\u2011therapy potency and safety.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-product-candidate-ipsc-derived-corneal-endothelial-cell-therapy\">Lead Product Candidate \u2013 iPSC\u2011Derived Corneal Endothelial Cell Therapy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Development Milestone<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Pre\u2011clinical efficacy<\/strong><\/td><td>Demonstrated restoration of corneal transparency in rabbit models (\u2265\u202f85\u202f% success).<\/td><\/tr><tr><td><strong>IND\u2011enabling studies<\/strong><\/td><td>Completed GLP toxicology; filing with NMPA planned Q2\u202f2026.<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Fuchs endothelial corneal dystrophy &amp; post\u2011surgical endothelial loss.<\/td><\/tr><tr><td><strong>Differentiation Yield<\/strong><\/td><td>&gt;\u202f92\u202f% CD\u201131\u207b\/CD\u201134\u207b\/ZO\u20111\u207a cells, surpassing industry benchmarks.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-outlook\">Market Opportunity &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Ophthalmic Cell\u2011Therapy Market:<\/strong> Projected to exceed <strong>\u00a512\u202fbillion<\/strong> by 2030, driven by an aging population and rising prevalence of corneal endothelial disorders.<\/li>\n\n\n\n<li><strong>Revenue Forecast (Resight\u2019s Lead Candidate):<\/strong> Assuming 5\u202f% market capture of \u2248\u202f1.2\u202fmillion annual cases, potential <strong>\u00a5800\u202fmillion<\/strong> (\u2248\u202fUS$110\u202fmillion) in sales by 2029.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Dual\u2011platform approach (iPSC + AI) offers faster development cycles and the ability to address multiple ocular targets, differentiating Resight from traditional biologics and gene\u2011therapy competitors.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding financing, product development timelines, and market potential for Resight Therapeutics. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48544,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,44,4466],"class_list":["post-48542","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-ophthalmology","tag-resight-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48542\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy\" \/>\n<meta property=\"og:description\" content=\"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48542\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T07:03:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-18T07:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy\",\"datePublished\":\"2025-11-18T07:03:24+00:00\",\"dateModified\":\"2025-11-18T07:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1804.webp\",\"keywords\":[\"Cell-therapy\",\"Ophthalmology\",\"Resight Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48542#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48542\",\"name\":\"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1804.webp\",\"datePublished\":\"2025-11-18T07:03:24+00:00\",\"dateModified\":\"2025-11-18T07:03:25+00:00\",\"description\":\"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48542\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48542#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48542","og_locale":"en_US","og_type":"article","og_title":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy","og_description":"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.","og_url":"https:\/\/flcube.com\/?p=48542","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-18T07:03:24+00:00","article_modified_time":"2025-11-18T07:03:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48542#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48542"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy","datePublished":"2025-11-18T07:03:24+00:00","dateModified":"2025-11-18T07:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48542"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48542#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","keywords":["Cell-therapy","Ophthalmology","Resight Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48542#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48542","url":"https:\/\/flcube.com\/?p=48542","name":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48542#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48542#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","datePublished":"2025-11-18T07:03:24+00:00","dateModified":"2025-11-18T07:03:25+00:00","description":"Resight Therapeutics, a China\u2011based cell\u2011therapy pioneer founded in September\u202f2024, announced the close of an Angel\u2011stage financing round led by Hofon Capital with co\u2011investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company\u2019s lead iPSC\u2011derived corneal endothelial cell (CEC) therapy as well as early\u2011stage projects powered by its proprietary AI\u2011augmented reprogramming platforms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48542#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48542"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48542#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","width":1080,"height":608,"caption":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48542#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Resight Therapeutics Secures Tens\u2011Millions RMB Angel Round to Accelerate iPSC\u2011Derived Corneal Endothelial Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48542"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48542\/revisions"}],"predecessor-version":[{"id":48545,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48542\/revisions\/48545"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48544"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}